{"id":"quetiapine-600mg","rwe":[],"tags":[],"safety":{"boxedWarnings":["Increased mortality in elderly patients with dementia-related psychosis"],"drugInteractions":["CYP3A4 inhibitors (e.g., ketoconazole) may increase quetiapine levels","CYP3A4 inducers (e.g., carbamazepine) may decrease quetiapine levels"],"commonSideEffects":[{"effect":"somnolence","drugRate":"18%","severity":"moderate"},{"effect":"dizziness","drugRate":"12%","severity":"mild"},{"effect":"weight gain","drugRate":"10%","severity":"moderate"},{"effect":"dry mouth","drugRate":"9%","severity":"mild"},{"effect":"constipation","drugRate":"8%","severity":"mild"},{"effect":"tachycardia","drugRate":"7%","severity":"mild"},{"effect":"hypertension","drugRate":"6%","severity":"mild"}],"contraindications":["Known hypersensitivity to quetiapine or any components of the formulation"],"specialPopulations":{"elderly":"Use with caution due to increased risk of adverse events","pregnant":"Category C; use only if potential benefit justifies potential risk to the fetus","lactating":"Not recommended due to potential adverse effects on the infant"}},"trials":[],"_chembl":null,"aliases":[],"patents":[{"expiry":"2021","number":"US5006528A"},{"expiry":"2022","number":"US5229382A"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$1.1667/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$426","description":"QUETIAPINE 150 MG TABLET","retrievedDate":"2026-04-07"}],"offLabel":[],"timeline":[{"date":"1997","type":"approval","milestone":"FDA approval for schizophrenia","regulator":"FDA"},{"date":"2004","type":"approval","milestone":"FDA approval for bipolar disorder","regulator":"FDA"},{"date":"2023","type":"clinical trial","milestone":"Investigational use for major depressive disorder","regulator":"N/A"}],"_dailymed":null,"aiSummary":"Quetiapine 600mg, marketed by AstraZeneca, is an atypical antipsychotic used primarily for the treatment of schizophrenia and bipolar disorder. It works by modulating dopamine and serotonin receptors in the brain, helping to stabilize mood and reduce psychotic symptoms. Despite its efficacy, quetiapine has a range of side effects, including somnolence, dizziness, and weight gain, which can impact patient adherence. The drug is also under investigation for additional indications, such as major depressive disorder. Safety concerns include warnings about increased mortality in elderly patients with dementia-related psychosis.","ecosystem":[],"mechanism":{"target":["serotonin 5-HT2A receptors","dopamine D2 receptors"],"novelty":"Quetiapine was one of the first atypical antipsychotics to offer a more favorable side effect profile compared to traditional antipsychotics.","modality":"oral tablet","drugClass":"atypical antipsychotic","explanation":"Quetiapine exerts its therapeutic effects by blocking serotonin and dopamine receptors, which helps to reduce psychotic symptoms and stabilize mood.","oneSentence":"Quetiapine is an atypical antipsychotic that acts as a serotonin and dopamine receptor antagonist.","technicalDetail":"Quetiapine has a high affinity for serotonin 5-HT2A receptors and moderate affinity for dopamine D2 receptors, as well as interactions with other neurotransmitter systems like histamine H1 and adrenergic α1 receptors."},"_scrapedAt":"2026-03-28T00:03:30.893Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"3%","launchDate":"1997","annualCostUS":"$1,200","currentRevenue":"$2.5 billion","patientPopulation":"Approximately 1 million patients in the US","peakSalesEstimate":"$3.0 billion"},"references":[],"biosimilars":[],"competitors":["Olanzapine (Zyprexa, Eli Lilly)","Risperidone (Risperdal, Janssen Pharmaceuticals)","Aripiprazole (Abilify, Otsuka Pharmaceutical)"],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":["schizophrenia","bipolar disorder"],"offLabel":["generalized anxiety disorder","post-traumatic stress disorder"],"pipeline":["major depressive disorder"]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00457197","phase":"PHASE4","title":"Quetiapine for Bipolar Disorder and Alcohol Dependence","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-03","conditions":"Bipolar Disorder, Alcohol Dependence","enrollment":90},{"nctId":"NCT01119014","phase":"PHASE4","title":"Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis","status":"COMPLETED","sponsor":"Anne Katrine Pagsberg","startDate":"2010-05","conditions":"Psychosis","enrollment":300},{"nctId":"NCT00457366","phase":"PHASE4","title":"A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2006-05","conditions":"Agitation","enrollment":72},{"nctId":"NCT01195363","phase":"PHASE4","title":"Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2007-04","conditions":"Bipolar Disorder","enrollment":28},{"nctId":"NCT01810380","phase":"PHASE3","title":"Brexpiprazole in Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-03","conditions":"Schizophrenia","enrollment":468},{"nctId":"NCT00790192","phase":"PHASE3","title":"Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-10","conditions":"Schizophrenia","enrollment":488},{"nctId":"NCT01213121","phase":"PHASE4","title":"Neurophysiologic Changes in Patients With Bipolar Depression","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2010-09","conditions":"Bipolar Depression","enrollment":60},{"nctId":"NCT00221468","phase":"PHASE3","title":"A Study of Quetiapine for the Treatment of Mood Disorders in Adolescents","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2003-06","conditions":"Mood Disorders","enrollment":20},{"nctId":"NCT00852631","phase":"PHASE3","title":"Seroquel XR in Adults With Schizophrenia","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Schizophrenia","enrollment":28},{"nctId":"NCT00521365","phase":"PHASE4","title":"Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-05","conditions":"Bipolar Disorder, Bipolar Affective Psychosis, Mania","enrollment":88},{"nctId":"NCT00837343","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder","status":"UNKNOWN","sponsor":"Guangzhou Mental Hospital","startDate":"2008-12","conditions":"Bipolar Disorder","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":["Teva Pharmaceuticals","Mylan Pharmaceuticals","Apotex Inc."],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Quetiapine 600mg","genericName":"Quetiapine 600mg","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"1997","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"US5006528A","territory":"US","patent_type":"","expiry_date":"2021-06-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"US5229382A","territory":"US","patent_type":"","expiry_date":"2022-06-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}